[1] |
LI Mei, LI Qiang.
Recent progress of targeting Nrf2-ferroptosis to treat brain injury after ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(2): 188-197.
|
[2] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[3] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
[4] |
WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng.
Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
|
[5] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[6] |
QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei.
Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
|
[7] |
FU Hong, TIAN Lei.
Individualized precision therapy for patients with ischemic stroke and hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
|
[8] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[9] |
DING Hao, GAO Zhenhua, ZHENG Yun.
Research progress of microRNA in diagnosis and treatment of prostate cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
|
[10] |
ZHOU Guangchen, LIU Yixi, ZHENG Yun.
Colorectal cancer and microRNA: research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
|
[11] |
HU Yin, YANG Dandan, XU Yichao, SHAO Rong, RUAN Zourong, JIANG Bo, CHEN Jinliang, LOU Honggang.
Application of artificial neural network model in bioequivalence study of candesartan cilexetil tablets
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 63-69.
|
[12] |
XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling.
Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
|
[13] |
LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun.
Function and regulation of miRNAs associated with Parkinson's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783.
|
[14] |
ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping.
Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
|
[15] |
CHE Jinjing.
Application of biomarkers in clinical development of biologics and bioanalytical strategies
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 22-31.
|